Crossmark

Informing and Empowering Patients and Clinicians to Make Evidence-Supported Outcome-Based Decisions in Relation to SGLT2 Inhibitor Therapies: The Use of the Novel Years of Drug administration (YoDa) Concept

Crossref DOI link: https://doi.org/10.1007/s40261-021-01105-7

Published Online: 2022-02-02

Published Print: 2022-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Varadhan, Lakshminarayanan https://orcid.org/0000-0003-1976-8071
Saravanan, Ponnusamy

Ali, Sarah N.

Hanif, Wasim

Patel, Vinod
License Information

Text and Data Mining valid from 2022-02-01

Version of Record valid from 2022-02-01
More Information

Article History

Accepted: 17 November 2021

First Online: 2 February 2022

Declarations

:

: No funding was received for this study.

: Vinod Patel has worked with a large number of pharmaceutical companies in the field of diabetes care, including Astra Zeneca, Boehringer Ingelheim, Knapp, MSD, Lilly, Novo, Sanofi, Takeda and Mylan. Sarah Ali is a consultant diabetologist on the National Institute for Health and Care Excellence Guidelines Committee. There are no conflicts of interest for the other authors.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: All authors contributed to the study conception and methods. Material preparation, data collection and analysis were performed by Lakshminarayanan Varadhan and Vinod Patel. The first draft of the manuscript was written by Lakshminarayanan Varadhan and all authors commented and contributed to various versions of the manuscript. All authors read and approved the final manuscript.

Document is current

Any future updates will be listed below